Patents Assigned to Amylin Pharmaceuticals, LLC
-
Publication number: 20140066370Abstract: The disclosure provides Polypeptide Conjugates with multiple improved pharmacological and pharmacokinetic properties and their use in treating various diseases and conditions, such as diabetes and/or obesity.Type: ApplicationFiled: November 23, 2010Publication date: March 6, 2014Applicant: Amylin Pharmaceuticals, LLCInventors: Behrouz Bruce Forood, Soumitra S. Ghosh, James L. Trevaskis, Chengzao Sun, Odile Esther Levy, Lawrence J. D'Souza, Christopher J. Soares
-
Publication number: 20140066368Abstract: Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.Type: ApplicationFiled: August 20, 2013Publication date: March 6, 2014Applicants: AstraZeneca Pharmaceuticals, LP, Amylin Pharmaceuticals, LLCInventors: Christine Marie Mack, Jonathan David Roth
-
Publication number: 20140056924Abstract: The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs (e.g., GLP-1(7-36)-NH2) and the like. The GLP-1 receptor agonist compound may be exenatide.Type: ApplicationFiled: October 3, 2013Publication date: February 27, 2014Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLCInventor: Eve VAN CAUTER
-
Publication number: 20140038891Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.Type: ApplicationFiled: May 17, 2013Publication date: February 6, 2014Applicants: AstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLCInventors: Kathryn S. Prickett, Andrew A. Young
-
Patent number: 8642544Abstract: The disclosure provides N-terminus conformationally constrained compounds, which may comprise peptide mimetics and/or amino acid substitutions, which may be used in peptides, such as GLP-1 receptor agonist compounds, to induce a ?-turn secondary structure at the N-terminus. The N-terminus conformationally constrained compounds may be used for research purposes; to produce GLP-1 receptor agonist compounds having improved GLP-1 receptor binding activity, enzymatic stability, or in vivo glucose lowering activity; and to develop GLP-1 receptor agonist compounds which have fewer amino acid residues. The disclosure also provides GLP-1 receptor agonist compounds, such as exendins, exendin analogs, GLP-1 (7-37), GLP-1 (7-37) analogs, comprising the N-terminus conformationally constrained compounds. The compounds are useful for treating various diseases, such as diabetes and obesity. The disclosure also provides methods for chemically synthesizing the N-terminus conformationally constrained compounds.Type: GrantFiled: March 26, 2010Date of Patent: February 4, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Josue Alfaro-Lopez, Abhinandini Sharma, Soumitra S. Ghosh
-
Patent number: 8636689Abstract: Pen injection devices (10) and methods of using a pen injection device are disclosed. Pen injection devices include a sterile dual transfer spike assembly (150) including a dual transfer spike defining a fluidic pathway; a first cartridge assembly (12) including a first cartridge (20) containing a first substance; a second cartridge assembly (14) including a second cartridge (30) containing a second substance; a plunger rod (50) translatable in a first direction; and a biasing mechanism (60) configured to bias the plunger rod in a second direction opposite the first direction. Methods of using a pen injection device having a first container, a second container, a plunger rod, and a biasing mechanism include activating the pen injection device, thereby creating a fluidic pathway between the first container and the second container; and translating the plunger rod at least once, thereby transferring a first substance from one container to the other container to mix with a second substance.Type: GrantFiled: July 16, 2008Date of Patent: January 28, 2014Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LPInventors: Reynaldo B. Halili, Jr., Victor Wei-Chung Chang, Phillip A. Estepa, Tyler J. Holschlag, Philip J. Simpson, David G. Matsuura
-
Publication number: 20130331322Abstract: Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.Type: ApplicationFiled: August 22, 2013Publication date: December 12, 2013Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLCInventors: Andrew A. Young, Bronislava Gedulin
-
Patent number: 8603969Abstract: The present invention relates to novel Pancreatic Polypeptide Family (“PPF”) polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50% sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY. Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif.Type: GrantFiled: February 11, 2005Date of Patent: December 10, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Odile Esther Levy, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett
-
Patent number: 8603761Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLPI receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.Type: GrantFiled: November 30, 2012Date of Patent: December 10, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Michalis Nicolaou, Frederick Charles Bancroft, John Patrick Herich, Aung Naing Lwin, Swati Gupta
-
Patent number: 8598314Abstract: Peptide-peptidase inhibitor conjugate molecules and methods of manufacture thereof are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.Type: GrantFiled: September 26, 2008Date of Patent: December 3, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Soumitra S. Ghosh, Josue Alfaro-Lopez, Lawrence J. D'Souza, Odile Esther Levy, Qing Lin, Christopher J. Soares
-
Patent number: 8598120Abstract: The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.Type: GrantFiled: February 1, 2012Date of Patent: December 3, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Christopher J. Soares, Michael R. Hanley, Diana Y. Lewis, David G. Parkes, Carolyn M. Jodka, Kathryn S. Prickett, Soumitra S. Ghosh, Christine M. Mack, Qing Lin
-
Publication number: 20130296225Abstract: The disclosure provides microcrystals of Y receptor agonists; microcrystalline pellets of Y receptor agonists, and microcrystalline suspensions of Y receptor agonists. Pharmaceutical compositions containing these microcrystals, microcrystalline pellets, and microcrystalline suspensions have prolonged pharmacokinetic profiles making them useful for once daily or once weekly administration.Type: ApplicationFiled: July 8, 2011Publication date: November 7, 2013Applicant: Amylin Pharmaceuticals LLCInventor: Steven Shijun Ren
-
Patent number: 8551947Abstract: Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.Type: GrantFiled: November 12, 2010Date of Patent: October 8, 2013Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LPInventors: Thomas R. Coolidge, Mario Ehlers
-
Publication number: 20130225485Abstract: Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the administration of an Amylin or an Amylin agonist to a subject in order to prevent, treat or control conditions or disorders associated with obesity, diet and nutrition.Type: ApplicationFiled: September 28, 2012Publication date: August 29, 2013Applicant: Amylin Pharmaceuticals, LLCInventor: Amylin Pharmaceuticals, LLC
-
Publication number: 20130209586Abstract: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.Type: ApplicationFiled: March 4, 2013Publication date: August 15, 2013Applicants: ASTRAZENECA LP, AMYLIN PHARMACEUTICALS, LLCInventors: AMYLIN PHARMACEUTICALS, LLC, ASTRAZENECA LP
-
Publication number: 20130203661Abstract: The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: ApplicationFiled: March 28, 2013Publication date: August 8, 2013Applicants: ASTRAZENECA PHARMACEUTICALS LP, Amylin Pharmaceuticals, LLCInventors: Amylin Pharmaceuticals, LLC, ASTRAZENECA PHARMACEUTICALS LP
-
Patent number: 8501693Abstract: The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.Type: GrantFiled: August 6, 2007Date of Patent: August 6, 2013Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LPInventors: Dennis Kim, Michael Trautmann
-
Publication number: 20130196913Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.Type: ApplicationFiled: March 25, 2013Publication date: August 1, 2013Applicants: AstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLCInventors: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
-
Patent number: 8497240Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.Type: GrantFiled: August 17, 2007Date of Patent: July 30, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le
-
Publication number: 20130184213Abstract: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.Type: ApplicationFiled: February 26, 2013Publication date: July 18, 2013Applicants: Astrazeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLCInventors: Kevin D. LAUGERO, Michael R. Hanley, Christine M. Mack, David G. Parkes, Andrew A. Young